Cepheid Inc (CPHD) 34.26 $CPHD Shares of CPHD U
Post# of 273258
Posted On: 09/02/2016 3:12:23 PM
Cepheid Inc (CPHD) 34.26 $CPHD
Shares of CPHD Up 21.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 24, 1:47PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.85% as of today's recent price of $36.25.
CPHD: 34.26 (unch)
Interesting CPHD Put And Call Options For October 21st
DividendChannel.com - Mon Aug 22, 10:46AM CDT
Investors in Cepheid saw new options begin trading today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPHD options chain for the new October 21st contracts and identified one put and...
CPHD: 34.26 (unch)
Moving Average Crossover Alert: Cepheid (CPHD)
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:31AM CDT
Cepheid (CPHD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
CPHD: 34.26 (unch)
21.0% Return Seen to Date on SmarTrend Cepheid Call (CPHD)
Comtex SmarTrend(R) - Wed Aug 17, 1:15AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.01% as of today's recent price of $36.00.
CPHD: 34.26 (unch)
Cepheid Shares Up 24.2% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Aug 09, 1:45PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 24.17% as of today's recent price of $36.94.
CPHD: 34.26 (unch)
Global Enteric Disease Testing Market 2016-2020 - Key Vendors are Alere, bioMrieux, Cepheid & DiaSorin - Research and Markets
BusinessWire - Tue Aug 09, 9:55AM CDT
Research and Markets has announced the addition of the "Global Enteric Disease Testing Market 2016-2020" report to their offering.
CPHD: 34.26 (unch)
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Thu Aug 04, 3:05PM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 34.26 (unch)
Henry Schein (HSIC) Tops Q2 Earnings, Sales; Slashes View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:46PM CDT
Henry Schein (HSIC) ended second quarter of 2016 on an impressive note, squarely beating the Zacks Consensus Estimate.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), HSIC: 164.25 (+1.27)
AmSurg (AMSG) Lags Q2 Earnings & Sales; Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:28AM CDT
AmSurg (AMSG) ended the second quarter of 2016 on a disappointing note, with quarterly numbers missing the Zacks Consensus Estimate on both fronts.
AMSG: 67.18 (+1.78), BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
Masimo (MASI) Beats Q2 Earnings, Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Masimo Corp reported earnings of 49 cents per share that beat the Zacks Consensus Estimate by 8 cents.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), MLAB: 112.83 (-0.55)
Fresenius Medical (FMS) Q2 Earnings & Sales Lag Estimates
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:56AM CDT
Fresenius Medical Care (FMS) reported adjusted earnings of 48 cents per American Depositary Share (ADS) in the second quarter of 2016, missing the Zacks Consensus Estimate by a penny.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), FMS: 44.67 (+1.07)
Genomic Health (GHDX) Q2 Loss Narrows Y/Y, Sales Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 2:11PM CDT
Genomic's (GHDX) second-quarter bottom line outcome improved year over year and came in line with the Zacks Consensus Estimate
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), GHDX: 27.05 (+0.38)
Wright Medical (WMGI) Posts Narrower Loss in Q2, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 1:52PM CDT
Wright Medical Group N.V. (WMGI) reported adjusted loss of 18 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 32 cents.
BABY: 40.36 (+0.65), WMGI: 24.65 (+0.04), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:18AM CDT
DexCom Inc. (DXCM) reported loss of 24 cents per share in the second quarter of 2016, much wider than the Zacks Consensus Estimate of a loss of 11 cents.
BABY: 40.36 (+0.65), DXCM: 92.01 (+0.30), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.69 (+0.26), CPHD: 34.26 (unch), LMNX: 21.01 (+0.08), MLAB: 112.83 (-0.55)
IDEXX (IDXX) Tops Q2 Earnings, Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:41AM CDT
IDEXX Laboratories Inc. (IDXX) reported second-quarter 2016 earnings per share (EPS) of 74 cents, up 23% year over year .
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), IDXX: 113.94 (+0.78)
Integer (ITGR) Misses on Q2 Earnings, Synergy View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 4:05PM CDT
Integer (ITGR) reported adjusted earnings of 56 cents per share in the second quarter of 2016, which missed the Zacks Consensus Estimate of 74 cents.
MASI: 59.69 (+0.26), ITGR: 24.45 (+0.45), NVTR: 6.86 (+0.01), CPHD: 34.26 (unch)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), HAE: 37.66 (+0.34), CPHD: 34.26 (unch)
Cepheid Up 20.5% Since SmarTrend Uptrend Call (CPHD)
Comtex SmarTrend(R) - Tue Aug 02, 1:55PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 1 month, Cepheid has returned 20.50% as of today's recent price of $35.85.
CPHD: 34.26 (unch)
Cepheid (CPHD) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:33AM CDT
Cepheid (CPHD) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.
CPHD: 34.26 (unch)
Shares of CPHD Up 21.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 24, 1:47PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.85% as of today's recent price of $36.25.
CPHD: 34.26 (unch)
Interesting CPHD Put And Call Options For October 21st
DividendChannel.com - Mon Aug 22, 10:46AM CDT
Investors in Cepheid saw new options begin trading today, for the October 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CPHD options chain for the new October 21st contracts and identified one put and...
CPHD: 34.26 (unch)
Moving Average Crossover Alert: Cepheid (CPHD)
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:31AM CDT
Cepheid (CPHD) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
CPHD: 34.26 (unch)
21.0% Return Seen to Date on SmarTrend Cepheid Call (CPHD)
Comtex SmarTrend(R) - Wed Aug 17, 1:15AM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 21.01% as of today's recent price of $36.00.
CPHD: 34.26 (unch)
Cepheid Shares Up 24.2% Since SmarTrend's Buy Recommendation (CPHD)
Comtex SmarTrend(R) - Tue Aug 09, 1:45PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 2 months, Cepheid has returned 24.17% as of today's recent price of $36.94.
CPHD: 34.26 (unch)
Global Enteric Disease Testing Market 2016-2020 - Key Vendors are Alere, bioMrieux, Cepheid & DiaSorin - Research and Markets
BusinessWire - Tue Aug 09, 9:55AM CDT
Research and Markets has announced the addition of the "Global Enteric Disease Testing Market 2016-2020" report to their offering.
CPHD: 34.26 (unch)
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Thu Aug 04, 3:05PM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
CPHD: 34.26 (unch)
Henry Schein (HSIC) Tops Q2 Earnings, Sales; Slashes View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 2:46PM CDT
Henry Schein (HSIC) ended second quarter of 2016 on an impressive note, squarely beating the Zacks Consensus Estimate.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), HSIC: 164.25 (+1.27)
AmSurg (AMSG) Lags Q2 Earnings & Sales; Cuts Sales View
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 9:28AM CDT
AmSurg (AMSG) ended the second quarter of 2016 on a disappointing note, with quarterly numbers missing the Zacks Consensus Estimate on both fronts.
AMSG: 67.18 (+1.78), BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
Masimo (MASI) Beats Q2 Earnings, Revenues; FY16 View Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:08AM CDT
Masimo Corp reported earnings of 49 cents per share that beat the Zacks Consensus Estimate by 8 cents.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), MLAB: 112.83 (-0.55)
Fresenius Medical (FMS) Q2 Earnings & Sales Lag Estimates
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:56AM CDT
Fresenius Medical Care (FMS) reported adjusted earnings of 48 cents per American Depositary Share (ADS) in the second quarter of 2016, missing the Zacks Consensus Estimate by a penny.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), FMS: 44.67 (+1.07)
Genomic Health (GHDX) Q2 Loss Narrows Y/Y, Sales Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 2:11PM CDT
Genomic's (GHDX) second-quarter bottom line outcome improved year over year and came in line with the Zacks Consensus Estimate
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), GHDX: 27.05 (+0.38)
Wright Medical (WMGI) Posts Narrower Loss in Q2, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 1:52PM CDT
Wright Medical Group N.V. (WMGI) reported adjusted loss of 18 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 32 cents.
BABY: 40.36 (+0.65), WMGI: 24.65 (+0.04), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
DexCom (DXCM) Q2 Loss Wider than Expected, Stock Down
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:18AM CDT
DexCom Inc. (DXCM) reported loss of 24 cents per share in the second quarter of 2016, much wider than the Zacks Consensus Estimate of a loss of 11 cents.
BABY: 40.36 (+0.65), DXCM: 92.01 (+0.30), MASI: 59.69 (+0.26), CPHD: 34.26 (unch)
Luminex (LMNX) Gets FDA Nod for Assays; Q2 Earnings Beat
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 10:11AM CDT
Luminex reported second-quarter 2016 adjusted earnings of 26 cents per share, which surpassed the Zacks Consensus Estimate of 18 cents.
MASI: 59.69 (+0.26), CPHD: 34.26 (unch), LMNX: 21.01 (+0.08), MLAB: 112.83 (-0.55)
IDEXX (IDXX) Tops Q2 Earnings, Revenues, FY16 View Up
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:41AM CDT
IDEXX Laboratories Inc. (IDXX) reported second-quarter 2016 earnings per share (EPS) of 74 cents, up 23% year over year .
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), CPHD: 34.26 (unch), IDXX: 113.94 (+0.78)
Integer (ITGR) Misses on Q2 Earnings, Synergy View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 4:05PM CDT
Integer (ITGR) reported adjusted earnings of 56 cents per share in the second quarter of 2016, which missed the Zacks Consensus Estimate of 74 cents.
MASI: 59.69 (+0.26), ITGR: 24.45 (+0.45), NVTR: 6.86 (+0.01), CPHD: 34.26 (unch)
Haemonetics (HAE) Lags Q1 Earnings, Tops Sales Estimates
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 2:33PM CDT
Haemonetics (HAE) started off fiscal 2017 on a mixed note, with its fiscal first quarter earnings figure missing the Zacks Consensus Estimate, while the top line figure beating.
BABY: 40.36 (+0.65), MASI: 59.69 (+0.26), HAE: 37.66 (+0.34), CPHD: 34.26 (unch)
Cepheid Up 20.5% Since SmarTrend Uptrend Call (CPHD)
Comtex SmarTrend(R) - Tue Aug 02, 1:55PM CDT
SmarTrend identified an Uptrend for Cepheid (NASDAQ:CPHD) on June 20th, 2016 at $29.75. In approximately 1 month, Cepheid has returned 20.50% as of today's recent price of $35.85.
CPHD: 34.26 (unch)
Cepheid (CPHD) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:33AM CDT
Cepheid (CPHD) has been on the move lately as the stock has risen by 10.8% in the past four weeks, and it is currently trading well above its 20-Day SMA.
CPHD: 34.26 (unch)
(0)
(0)Scroll down for more posts ▼